Video

Dr Daniel Petrylak Explains PD-1, PD-L1 Expression in Bladder Cancer Treatment

New study results being presented at the American Society of Clinical Oncology's annual meeting in Chicago found that the PD-1 and PD-L1 biomarkers can be used to determine response and resistance, explained Daniel P. Petrylak, MD.

New study results being presented at the American Society of Clinical Oncology's annual meeting in Chicago found that the PD-1 and PD-L1 biomarkers can be used to determine response and resistance, explained Daniel P. Petrylak, MD, professor of medicine (medical oncology) and of urology at the Yale Cancer Center. He will be presenting the results of a trial on PD-1 and PD-L1 expression in bladder cancer.

"We need to diligently assess tissue in these patients to help understand the marker pattern and how it can be used to treat them," he said.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Dr Carrie Kitko
Dr Ibrahim Aldoss
1 expert is featured in this series.
Miriam Freimer, MD
Dr Pankit Vachhani
Dr Ibrahim Aldoss
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo